Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY
TBPH•Q2 earnings and revenue
Theravance Biopharma posted a Q2 GAAP net loss of USD 5.9 million, swinging from a year-earlier profit of USD 54.8 million.
Revenue rose 11% year over year to USD 20.7 million, entirely from Viatris collaboration revenue tied to YUPELRI.
Zymeworks acquisition terms
Zymeworks agreed to buy the company for USD 17 per share in cash plus a CVR; closing is expected in the second half of 2026.
Costs declined in the quarter
R&D expense fell to USD 4.7 million from USD 10.5 million; SG&A dropped to USD 14.2 million from USD 18.4 million.
Transaction-related costs tied to the Zymeworks deal totaled USD 6.1 million; restructuring expense was USD 4 million.
